Common Contracts
16 similar Clinical Investigation Agreement contracts
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS BETWEENClinical Investigation Agreement • January 24th, 2022
IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA, headquartered in Via Albertoni 15, 40138 Bologna, tax code: 92038610371, VAT registration number: 02553300373, legally represented by the Director of the U.O.C. Research and Innovation, Dott.ssa Luigia Scudeller, delegated to sign this deed under the resolution no. 28 of 02/02/2018, as confirmed by resolution no. 255 of 31/10/201 (hereinafter the “Entity")
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGSClinical Investigation Agreement • October 13th, 2021
(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted , (position of signatory) (hereinafter ” ”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGSClinical Investigation Agreement • April 26th, 2021
(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted , (position of signatory) (hereinafter ” ”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGSClinical Investigation Agreement • April 26th, 2021
(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted , (position of signatory) (hereinafter ” ”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGSClinical Investigation Agreement • March 1st, 2021
(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted , (position of signatory) (hereinafter ” ”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS BETWEENClinical Investigation Agreement • November 24th, 2020
AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA - IRCCS, headquartered in via Albertoni 15, 40138 Bologna, tax code: 92038610371, VAT registration number: 02553300373, legally represented by (hereinafter the “Entity"), Interim manager of the S.C. Research and Innovation, Dr. Gianluigi Magri, referred to the assignment with the note of the General Manager prot. 7214 of 06.03.2020, extended with the note of the General Manager prot.35640 of 24.11.2020
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS “_________________________________"Clinical Investigation Agreement • September 7th, 2020
_______________ (insert name of Healthcare Facility) (hereinafter the “Entity"), headquartered in _____, tax code and VAT no. ___, through its Legal Representative ________, in the capacity of _____________(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted _________________, (position of signatory) (hereinafter ”______”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS BETWEENClinical Investigation Agreement • August 20th, 2020
AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI, headquartered in via Albertoni 15, 40138 Bologna, tax code: 92038610371, VAT registration number: 02553300373, legally represented by (hereinafter the “Entity"), _____________
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS “_________________________________"Clinical Investigation Agreement • July 28th, 2020
_______________ (insert name of Healthcare Facility) (hereinafter the “Entity"), headquartered in _____, tax code and VAT no. ___, through its Legal Representative ________, in the capacity of _____________ (indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted _________________, (position of signatory) (hereinafter ”______”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGSClinical Investigation Agreement • February 21st, 2020
(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted , (position of signatory) (hereinafter ” ”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS BETWEENClinical Investigation Agreement • February 13th, 2020
(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted , (position of signatory) (hereinafter ” ”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS “_________________________________"Clinical Investigation Agreement • February 12th, 2020
_______________ (insert name of Healthcare Facility) (hereinafter the “Entity"), headquartered in _____, tax code and VAT no. ___, through its Legal Representative ________, in the capacity of _____________(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted _________________, (position of signatory) (hereinafter ”______”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS “_________________________________"Clinical Investigation Agreement • January 21st, 2020
_______________ (insert name of Healthcare Facility) (hereinafter the “Entity"), headquartered in _____, tax code and VAT no. ___, through its Legal Representative ________, in the capacity of _____________(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted _________________, (position of signatory) (hereinafter ”______”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGSClinical Investigation Agreement • January 15th, 2020
_L’Azienda Socio-Sanitaria Territoriale (ASST) di Lecco (hereinafter the “Entity"), headquartered in Lecco via dell’Eremo 9/11, tax code and VAT no. 03622120131, through Avv. Luisa Fumagalli, Director of U.O.C. Affari Generali with the powers to enter into this Agreement by delegation of Director General
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGSClinical Investigation Agreement • December 17th, 2019
(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted , (position of signatory) (hereinafter ” ”) with the powers to enter into this Agreement
CLINICAL INVESTIGATION AGREEMENT FOR THE DRUGS “_________________________________"Clinical Investigation Agreement • December 17th, 2019
_______________ (insert name of Healthcare Facility) (hereinafter the “Entity"), headquartered in _____, tax code and VAT no. ___, through its Legal Representative ________, in the capacity of _____________(indicate whether Director General, CEO, Extraordinary Commissioner, etc.), who has granted _________________, (position of signatory) (hereinafter ”______”) with the powers to enter into this Agreement
